Sapient Capital LLC reduced its position in Liquidia Corporation (NASDAQ:LQDA – Free Report) by 23.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 49,600 shares of the company’s stock after selling 15,000 shares during the period. Sapient Capital LLC’s holdings in Liquidia were worth $1,708,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Federated Hermes Inc. purchased a new position in shares of Liquidia during the 3rd quarter valued at $7,290,000. Caprock Group LLC purchased a new stake in Liquidia in the 3rd quarter worth $37,114,000. Farallon Capital Management LLC raised its holdings in Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the period. Apis Capital Advisors LLC bought a new stake in Liquidia during the third quarter valued at about $9,569,000. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Liquidia in the third quarter valued at about $1,536,000. 64.54% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Liquidia
In related news, CEO Roger Jeffs sold 25,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $57.04, for a total value of $1,426,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,198,095 shares of the company’s stock, valued at approximately $68,339,338.80. This trade represents a 2.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen M. Bloch sold 318,893 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the completion of the sale, the director owned 1,870,042 shares in the company, valued at $93,932,209.66. This represents a 14.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 1,022,713 shares of company stock worth $44,689,753. 25.60% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on LQDA
Liquidia Trading Up 0.1%
Shares of Liquidia stock opened at $56.97 on Tuesday. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $59.75. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The business has a 50-day moving average price of $40.15 and a 200-day moving average price of $36.27. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of 406.96 and a beta of 0.41.
Liquidia (NASDAQ:LQDA – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. Equities research analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current fiscal year.
Liquidia Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Stories
- Five stocks we like better than Liquidia
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Corporation (NASDAQ:LQDA – Free Report).
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
